olaparib,bevacizumab
roche,astrazeneca,merck
['vance', 'solo1', 'olaparib', 'able,(-kable),(-eable)', 'ovarian', 'paola-1']
olaparib shows durable clinical benefits in hrd+ patients with advanced #ovariancancer: results from the phase iii solo1/gog-3004 and paola-1/engot-ov25 trials at #esmo22. to know more 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.